Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A critical view of the BJH publication on the lack of benefit of second-line daratumumab in patients with functional high-risk multiple myeloma.

British journal of haematology·2026
Same author

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Blood·2026
Same author

Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study.

JCO clinical cancer informatics·2026
Same author

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.

The Lancet. Haematology·2025
Same author

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

The New England journal of medicine·2025
Same journal

Early versus standard anti-thymocyte globulin administration in haploidentical transplantation using post-transplant cyclophosphamide: a pilot comparative study.

Annals of hematology·2026
Same journal

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology·2026
Same journal

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026
Same journal

A case report of CD4<sup>-</sup> CD8<sup>+</sup> CD56<sup>-</sup> TCRγδ<sup>+</sup> T-large granular lymphocytic leukaemia with severe aplastic anemia and a PNH clone.

Annals of hematology·2026
Same journal

An assessment of the effectiveness of hydroxyurea therapy in children and adolescents with sickle cell anaemia at Kenyatta National Hospital.

Annals of hematology·2026
Same journal

Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation.

Annals of hematology·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Blinatumomab in relapsed/refractory diffuse large B cell lymphoma

Ruben Van Dijck1, Ann Janssens2, Daan Dierickx2

  • 1Department of Internal Medicine, Leuven University Hospitals, Leuven, Belgium.

Annals of Hematology
|August 6, 2017
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

746

Related Experiment Videos

Last Updated: Feb 25, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

746